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Abstract:  We present a 78-year-old patient who developed refractory glaucoma following a fungal infection of the 
corneal incision after cataract extraction with posterior chamber intraocular lens implantation. An anterior chamber 
injection of 0.1 ml recombinant tissue plasminogen activator (25 mcg/0.1 mL) was performed to improve the trabecular 
meshwork outflow facility compromised secondary to fibrin blockade. The intraocular pressure dropped dramatically 
from 48 mmHg to 10 mmHg postoperatively, negating the need for glaucoma surgery. 
INTRODUCTION 
  Recombinant tissue plasminogen activator (rTPA) in 
ophthalmology has been used in the treatment of hyphema 
[1]
  and fibrin formation after cataract surgery [2, 3].
  In 
glaucoma surgery, rTPA has been used for tube shunt 
occlusion, bleb failure and fibrin effusion [4, 5].
 
  We present a case of refractory glaucoma following a 
fungal infection of a corneal incision after cataract extraction 
that was successfully treated with intracameral injection of 
rTPA. 
CASE REPORT 
  A 78-year-old Caucasian female presented with a red 
painful left eye at her 1 month postoperative visit after 
uneventful cataract extraction with posterior chamber 
intraocular lens implantation. The visual acuity (VA) was 
20/20 in right eye (OD), 20/70 in left eye (OS), and the 
intraocular pressure (IOP) was 14 mmHg in OD and 20 
mmHg in OS. Slit lamp examination of the OS revealed a 
corneal ulcer measuring 1.5mm horizontally and 6 mm 
vertically corresponding to the temporal clear corneal 
incision, a deep anterior chamber with 1+ flare and a 
posterior chamber implant in the capsular bag. 
  Treatment was started with topical fortified vancomycin 
25 mg/mL and tobramycin 15 mg/mL hourly, scopolamine 
TID and oral moxifloxacin 400 mg daily. In the following 
days, the ulcer extended vertically to 7 mm, a hypopyon 
formed, a fibrin clot grew to fill the anterior chamber and the 
IOP rose to 24 mmHg. Corneal scrapings showed fungal 
elements and treatment was changed to oral voriconazole 
200 mg BID, topical voriconazole 1% hourly, topical 
moxifloxacin 0.5% every 2 hours and continued with oral 
moxifloxacin. The vision in the OS dropped precipitously to 
counting fingers at 3ft on day 2 to hand motion on day 3. On 
day 4, the patient was hospitalized with an IOP of 41 mmHg, 
more fibrin and a larger hypopyon. Microbiology reported 
growth of methicillin resistant staphylococcus aureus   
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(MRSA) sensitive to vancomycin and the treatment was 
changed to fortified vancomycin and voriconazole hourly, 
dorzolamide-timolol fixed combination BID, brimonidine 
TID, atropine and oral acetazolamide sequel 500 mg BID, 
voriconazole and moxifloxacin. Despite the intensive topical 
treatment and intravenous mannitol, the IOP fluctuated in the 
range of 40-57 mmHg. After informed consent, the patient 
agreed to the use of rTPA, which was prepared by the 
hospital pharmacy staff from lyophilized recombinant tPA 
(Activase, Genetech Inc, San Francisco). An anterior 
chamber injection of 0.1 ml rTPA (25 mcg/0.1 mL) preceded 
by aspiration of 0.08 ml of aqueous humor, was performed to 
clear the fibrin (Fig 1A). On postoperative day 4, slit lamp 
examination showed no change in the ulcer margins and a 
shallow anterior chamber with hyphema covering the 
hypopyon (Fig 1B). IOP in OS was 10 mmHg with only 
brimonidine TID. On postoperative day 15, the patient’s VA 
was CF at 1ft, slit lamp examination revealed a markedly 
retracted fibrin clot with traces of blood, no hyphema, 
minimal hypopyon and an IOP of 18 mmHg without 
glaucoma medication (Fig. 1C). At follow-up visits (week 3, 
week 5, week 8, week 12), the IOP had a favorable evolution 
(16, 15, 12, 31 and 18 mmHg, respectively) with 
brimonidine. 
DISCUSSION 
  Though acute inflammation within the eye may reduce 
aqueous secretion and lower the intraocular pressure, 
inflammatory material, consisting of white blood cells, 
macrophages and proteins, may obstruct the trabecular 
meshwork [5]. Additionally, inflammatory scarring may lead 
to peripheral anterior synechiae resulting in angle-closure 
glaucoma. In this case the secondary glaucoma was thought 
to be due to the inflammatory debris blocking the outflow of 
aqueous through the trabecular meshwork. 
  A surgical approach such as a trabeculectomy or tube 
shunt with an infectious corneal ulcer is not ideal for fear of 
intraocular extension of the infection, further intraocular 
inflammation or bleeding. A cyclodestructive procedure such 
as laser cyclophotocoagulation would encourage further 
inflammation and may lead to phthisis in this clinical setting. 
Therefore, the minimally invasive technique of rTPA 
injection became the favored initial approach to lower the 76    The Open Ophthalmology Journal, 2009, Volume 3  Katz et al. 
IOP by dissolution of the fibrin clot. The effect of rTPA on 
the fibrin clot was seen in the next two hours but as a minor 
complication, a minimal hyphema covered the hypopyon. 
Nevertheless, the hyphema completely disappeared in 10 
days and there was no further bleeding. 
  rTPA is a genetically cloned serine protease that works 
by converting plasminogen into plasmin. It promotes 
degradation of the fibrin only at the clot surface and it is not 
associated with systemic fibrinolysis. rTPA has been 
effectively used in the past in traumatic hyphema [1], 
fibrinous effusion after cataract surgery in adults [2], severe 
post cataract fibrinous membrane in pediatric groups [3], 
glaucoma surgery [4, 5 ] and subretinal hemorrhage [6]. The 
response to rTPA may have been coincident with an 
improving clinical course and unrelated to the drug. The 
potential complications related to the use of rTPA are 
corneal edema and anterior chamber turbidity, which results 
from immediate fibrinolysis products [5]. 
  In conclusion, in markedly inflamed eyes with a fibrin 
blockade of aqueous outflow, the use of intracameral rTPA 
should be considered to lower IOP in eyes resistant to topical 
and systemic medications. 
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Fig. (1). ( A) Slit lamp photograph 2 hours post rTPA injection showing fibrin clot retraction superiorly (white arrow) and marked 
conjunctival congestion and chemosis. (B) Slit lamp photograph on day 4 post intracameral rTPA showing shallow anterior chamber, 
hyphema overlying the hypopyon (white arrow) and no progression of the corneal abscess. (C) Slit lamp photograph on day 15 post 
intracameral rTPA showing markedly reduced fibrin clot with minimal hypopyon. 